




PHARMACEUTICAL 2018

RENOVARO BIOSCIENCES INC.
Rank 241 of 342





RealRate

PHARMACEUTICAL 2018

RENOVARO BIOSCIENCES INC. Rank 241 of 342

The relative strengths and weaknesses of RENOVARO BIOSCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RENOVARO BIOSCIENCES INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 51% points. The greatest weakness of RENOVARO BIOSCIENCES INC. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is 6.5%, being 39% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	4,199
Cost of Goods Sold	0
Intangible Assets	124
Liabilities, Current	2,989
Liabilities, Non-Current	0
Other Assets	199
Other Compr. Net Income	0
Other Expenses	962
Other Liabilities	0
Other Net Income	193
Other Revenues	0
Property and Equipment	0
Research and Development	63
Selling, General and Administrative Expense	1,560

Output Variable	Value in 1000 USD
Assets	4,522
Liabilities	2,989
Expenses	2,586
Revenues	0
Stockholders Equity	1,533
Net Income	-2,393
Comprehensive Net Income	-2,393
Economic Capital Ratio	6.5%